DiaMedica Therapeutics Inc. Common Stock DMAC
Key Stats
- Today's Range
- $6.74 – $7.13
- 50-Day Range
- $5.25 – $8.53
- 52-Week Range
- $3.58 – $10.42
- Volume
- 140K shs
- Average Volume
- 196K shs
- Market Cap
- $370.47 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 9.66
- Price / Sales
- —
Short Interest
- Short Interest
- 0.05%
- Days to Cover
- 1.00
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Related Stocks
Compare head-to-head: DMAC vs LLY·DMAC vs JNJ·DMAC vs ABBV·DMAC vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.